CASE REPORT article

Front. Pediatr.

Sec. Pediatric Immunology

Volume 13 - 2025 | doi: 10.3389/fped.2025.1570600

CASE REPORT: Clinical Manifestations of Uncommon Monogenic Disorders: Revisiting Activated phosphoinositide 3-kinase delta syndrome 2 (APDS2)

Provisionally accepted
  • 1Hadassah Medical Center, Jerusalem, Israel
  • 2Sheba Medical Center, Ramat Gan, Tel Aviv District, Israel
  • 3Shaare Zedek Hospital, Jerusalem, Jerusalem, Israel

The final, formatted version of the article will be published soon.

Aim: Pediatricians are trained to identify recurrent or unusual infections in children, prompting evaluation for inborn errors of immunity (IEI). Some monogenic IEI, however, may present atypically. This study describes our experience with children diagnosed with activated phosphoinositide 3-kinase delta syndrome (APDS2) including unusual presentations.: A retrospective review was conducted on two children diagnosed with APDS2 at Shaare Zedek and Sheba Tel-Hashomer Medical Centers in Israel. Both patients underwent immune assessments, genetic testing, and treatment between 2019 and 2024. Results: Two patients, a 17-year-old female (P1) and a 7-year-old male (P2), were diagnosed with APDS2 after presenting with recurrent juvenile parotitis (P1) and severe lymphadenopathy (P2). Immunologic evaluation revealed hypogammaglobulinemia and combined immune deficiency. Genetic testing identified PIK3R1 variants (c.1425+1G>T in P1 and c.1425+1G>C in P2). Both received intravenous immunoglobulins and prophylactic antibiotics. P2 was treated with rapamycin, leading to resolution of lymphadenopathy. Conclusion: This report highlights the clinical presentation of APDS2, a rare monogenic IEI in children, including the atypical manifestation of RJP and the common feature of lymphadenopathy. Pediatricians should stay vigilant for red flags of IEI during clinical evaluations, as early diagnosis and multidisciplinary care are crucial for effective management.

Keywords: APDS2, PIK3R1, inborn errors of immunity, combined immune deficiencies, primary immune deficiencies (PID)

Received: 03 Feb 2025; Accepted: 11 Apr 2025.

Copyright: © 2025 Shamriz, Mandola, Simon, Lev, Attal, Nadler, Barel, Khavkin, Eisenberg, Somech and Toker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Oded Shamriz, Hadassah Medical Center, Jerusalem, Israel
Ori Toker, Shaare Zedek Hospital, Jerusalem, Jerusalem, Israel

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more